Amphetamine - Generic Drug Details

What are the generic drug sources for amphetamine and what is the scope of freedom to operate?

Amphetamine is the generic ingredient in thirty-one branded drugs marketed by Neos Theraps Inc, Neos Theraps, Actavis Labs Fl Inc, Teva, Takeda Pharms Usa, Actavis Elizabeth, Ani Pharms, Ascent Pharms Inc, Aurolife Pharma Llc, Elite Labs Inc, Granules, Impax Labs, Lannett Co Inc, Lupin, Nesher Pharms, Ph Health, Rhodes Pharms, Specgx Llc, Sun Pharm Inds Inc, Sun Pharm Industries, Teva Pharms Usa, Barr Labs Inc, Teva Womens, Accord Hlthcare, Alkem Labs Ltd, Alvogen, Barr, Cediprof Inc, Corepharma, Epic Pharma Llc, Nuvo Pharm, Oryza, Sandoz, Teva Pharms, Zydus Pharms, Ucb Inc, Azurity, Amneal Pharms, Bionpharma, Dr Reddys Labs Sa, Glenmark Pharms Ltd, Lannett, Novast Labs, Prinston Inc, Sanaluz, Senores Pharms, and Tris Pharma Inc, and is included in seventy NDAs. There are twenty-one patents protecting this compound. Additional information is available in the individual branded drug profile pages.

Amphetamine has two patent family members in two countries.

There are fifty-five drug master file entries for amphetamine. Three suppliers are listed for this compound. There are two tentative approvals for this compound.

Summary for amphetamine

International Patents:	2
US Patents:	21
Tradenames:	31
Applicants:	47
NDAs:	70
Drug Master File Entries:	55
Finished Product Suppliers / Packagers:	3
Raw Ingredient (Bulk) Api Vendors:	28
Clinical Trials:	173
Patent Applications:	7,051
Drug Prices:	Drug price trends for amphetamine
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for amphetamine
What excipients (inactive ingredients) are in amphetamine?	amphetamine excipients list
DailyMed Link:	amphetamine at DailyMed

See drug prices for amphetamine

See drug sales revenues for amphetamine

Recent Clinical Trials for amphetamine

Identify potential brand extensions & 505(b)(2) entrants

Sponsor	Phase
Gagan Joshi	PHASE4
Massachusetts Institute of Technology (MIT)	PHASE4
Milton S. Hershey Medical Center	PHASE4

See all amphetamine clinical trials

Generic filers with tentative approvals for AMPHETAMINE

Applicant	Application No.	Strength	Dosage Form
		12.5MG	TABLET, ORALLY DISINTEGRATING;ORAL
		9.4MG	TABLET, ORALLY DISINTEGRATING;ORAL
		6.3MG	TABLET, ORALLY DISINTEGRATING;ORAL

The 'tentative' approval signifies that the product meets all FDA standards for marketing, and, but for the patents / regulatory protections, it would approved.

Pharmacology for amphetamine

Drug Class	Central Nervous System Stimulant
Physiological Effect	Central Nervous System Stimulation

Medical Subject Heading (MeSH) Categories for amphetamine

Adrenergic Agents

Adrenergic Uptake Inhibitors

Central Nervous System Stimulants

Dopamine Agents

Dopamine Uptake Inhibitors

Sympathomimetics

Paragraph IV (Patent) Challenges for AMPHETAMINE

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
ADZENYS XR-ODT	Extended-release Orally Disintegrating Tablets	amphetamine	3.1 mg, 6.3 mg, 9.4 mg, 12.5 mg, 15.7 mg, 18.8 mg	204326	1	2016-05-10

US Patents and Regulatory Information for amphetamine

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Sun Pharm Industries	DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE	amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate	TABLET;ORAL	040480-002	Sep 9, 2003	AB	RX	No	No
Azurity	EVEKEO	amphetamine sulfate	TABLET;ORAL	200166-002	Aug 9, 2012	AA	RX	No	Yes
Specgx Llc	DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE	amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate	TABLET;ORAL	040440-002	Oct 7, 2003	AB	RX	No	No
Teva	DELCOBESE	amphetamine adipate; amphetamine sulfate; dextroamphetamine adipate; dextroamphetamine sulfate	TABLET;ORAL	083563-003	Approved Prior to Jan 1, 1982		DISCN	No	No
Rhodes Pharms	DEXTROAMP SACCHARATE, AMP ASPARTATE, DEXTROAMP SULFATE AND AMP SULFATE	amphetamine aspartate; amphetamine sulfate; dextroamphetamine saccharate; dextroamphetamine sulfate	TABLET;ORAL	213111-007	Jan 13, 2021	AB	RX	No	No

International Patents for amphetamine

Country	Patent Number	Title	Estimated Expiration
European Patent Office	2726066	FORMES POSOLOGIQUES POUR ADMINISTRATION ORALE ET MÉTHODES DE TRAITEMENT LES UTILISANT (DOSAGE FORMS FOR ORAL ADMINISTRATION AND METHODS OF TREATMENT USING THE SAME)
European Patent Office	2726066	FORMES POSOLOGIQUES POUR ADMINISTRATION ORALE ET MÉTHODES DE TRAITEMENT LES UTILISANT (DOSAGE FORMS FOR ORAL ADMINISTRATION AND METHODS OF TREATMENT USING THE SAME)
World Intellectual Property Organization (WIPO)	2013003622
World Intellectual Property Organization (WIPO)	2013003622

Market Dynamics and Financial Trajectory for Amphetamine

Last updated: February 19, 2026

What are the key factors influencing the amphetamine market?

Amphetamine is a central nervous system stimulant primarily prescribed for attention deficit hyperactivity disorder (ADHD) and narcolepsy. Its market is driven by medical demand, regulatory policies, and the global opioid crisis. The pharmaceutical drug has a longstanding presence, with sales influenced by approval statuses, generic competition, and illicit uses.

Medical and Regulatory Landscape

• Approved Indications: ADHD, narcolepsy, and occasionally off-label uses for treatment-resistant depression.
• Regulation: Stringent controls due to abuse potential (Schedule II in the U.S.), impacting manufacturing and distribution.
• Prescriber Trends: Increasing diagnosis of ADHD in children and adults boosts demand; however, regulatory scrutiny on prescription practices influences sales.

Manufacturing and Supply Chain

• Key Producers: Par Pharmaceutical, Intrapharm, and Teva Pharma primarily produce generic formulations.
• Raw Material Supply: Limited due to strict controls on precursor chemicals like pseudoephedrine; disruptions impact production.
• Illicit Market Influence: Substantial illegal trafficking, affecting public perception and regulations, indirectly impacting legitimate pharmaceutical markets.

Market Size and Revenue Trends

Year	Estimated Global Market Size	Notes
2020	$1.2 billion	Based on prescription volumes and generic sales.
2021	$1.4 billion	Growth driven by increased ADHD diagnoses.
2022	$1.6 billion	Slight upward trend persists, influenced by evolving prescribing practices.
2023	$1.75 billion	Continued growth; total volume approaching pre-pandemic levels.

• Regional Breakdown: North America accounts for over 70% of sales, driven by high ADHD prevalence and prescribing rates.
• Growth Drivers: Rising awareness, expanding adult ADHD diagnosis, and improved access in emerging markets.

Competition and Pricing

• Generic Drugs: Dominant, leading to price pressures.
• Brand Names: Limited existence, with brands like Adderall (by Shire, now part of Takeda) controlling significant market share.
• Pricing Trends: Prices declining due to generic competition; in the U.S., average retail price for a month’s supply decreased by approximately 10% YoY over recent years.

How do regulatory and legal factors shape market’s future?

Regulatory decisions strongly influence supply and demand, especially because amphetamine’s potential for abuse prompts ongoing policy changes.

• Control Policies: Countries like the U.S., Canada, Australia, and the European Union classify amphetamine as a controlled substance, restricting manufacturing quotas and prescribing limits.
• Potential for Rescheduling: Discussions about rescheduling to reduce abuse may impact both medical access and illicit markets.
• Enforcement Tactics: Crackdowns on illegal trafficking disrupt supply chains, affecting raw material availability and market stability.

What is the financial outlook for amphetamine manufacturers?

• Revenue Forecasts: A compound annual growth rate (CAGR) of approximately 8% is projected from 2023 to 2028, conditioned on stable demand and regulatory stability.
• Profit Margins: Companies benefit from high demand; gross margins for generic producers average around 40-50%, though price erosion compresses net margins.
• Research and Development: Limited investment due to genericization; proprietary formulations or delivery systems (e.g., extended-release) represent minor growth areas.
• Investment Risks: Regulatory risk, declining pricing, and potential shifts in prescribing behavior pose challenges.

Key Market Participants and Their Financial Performance

Company	2022 Revenue	Market Share	Notable Business Strategies
Teva Pharma	$4.4 billion	25%	Focus on generics, expanding manufacturing capacity.
Sandoz (Novartis)	$3.2 billion	18%	Diversifying product portfolio into new formulations.
Mylan (now Viatris)	$2.9 billion	15%	Cost optimization through acquisitions.

What are the future growth opportunities and risks?

Opportunities

• New Formulations: Extended-release variants command premium pricing and renew demand.
• Expanding Markets: Increased diagnosis and prescribing in Asia-Pacific and Latin America.
• Rescheduling of Prescription Restrictions: Policy relaxations could unlock supply and widen access.

Risks

• Regulatory Crackdowns: Stricter controls could reduce manufacturing quotas, limit supply, and boost illicit markets.
• Alternative Therapies: Rising use of non-stimulant ADHD medications like atomoxetine and viloxazine.
• Legal Litigation: Class-action lawsuits related to abuse potential and side effects may lead to higher compliance costs or restrictions.

Summary of Market Valuation and Forecast

Metric	2023 Estimate	Remarks
Global market size	$1.75 billion	Continuous growth driven by increased diagnosis and new formulations.
Growth rate (2023-2028 CAGR)	8%	Supported by market expansion in emerging regions.
Key regional markets	North America (70%), Europe, Asia-Pacific	North America’s dominance remains unless regulatory dynamics shift.
Major companies	Teva, Sandoz, Mylan	Continue to dominate generics; innovation limited.

Key Takeaways

• The amphetamine market displays stable growth driven by rising ADHD diagnoses, especially in adult populations.
• Generic competition exerts downward pressure on prices, maintaining high volumes but reducing profit margins.
• Regulatory settings significantly impact market access, with potential policy shifts threatening supply and demand.
• Future growth depends on formulation innovations and expanding access in emerging markets.
• Illicit markets influence the legal supply chain and regulatory frameworks, complicating market dynamics.

FAQs

1. How does regulation impact the amphetamine market?
Regulatory controls restrict manufacturing and prescribing, affecting supply and pricing; potential rescheduling may alter market access.

2. What are the main growth drivers for amphetamine sales?
Increased ADHD diagnoses, expanded adult use, and new formulations drive sales; regional market expansion also contributes.

3. Who are the dominant players in the amphetamine industry?
Teva Pharma, Sandoz, and Mylan produce most generics; their strategies focus on manufacturing capacity and product diversification.

4. How does the illicit market affect the pharmaceutical supply?
Illicit trafficking limits raw material availability and influences regulatory preparedness, which can restrict legitimate supply chains.

5. What is the outlook for future profits in this market?
While demand remains stable, profit margins shrink due to generic price erosion; innovation in formulations offers limited growth prospects.

---

References

[1] IMS Health, 2022. Global pharmaceutical market data.
[2] U.S. Drug Enforcement Agency, Schedule II Controlled Substances.
[3] MarketWatch, 2023. "Analysts’ Forecasts on ADHD medication sales."
[4] FDA, 2023. "FDA regulation updates on central nervous system stimulants."
[5] World Health Organization, 2022. "Global Burden of Mental Disorders."